Consensus Atossa Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.57 ^USD	-2.48%		+5.37%	+78.41%

May. 15	Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial	MT
May. 15	Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial	CI

4c10e3ba5.aA-_CufcyQCoLonfrETylhYVWq_CTGmt0atilaUXa58.D17VM52wlkzNFuG95wu932NyD5rvFRjftJoN1pJUM_BQP-dG1L2getJB0A~c99af935a2ee154d46e0a61c47c4bb7f

Atossa Therapeutics Rises After HC Wainwright Starts Coverage with Buy Rating	Feb. 12	MT
HC Wainwright Initiates Atossa Therapeutics With Buy Rating, Price Target is $4	Feb. 12	MT
Cantor Fitzgerald Starts Atossa Therapeutics at Overweight With $5 Price Target	23-09-08	MT
Maxim Group Adjusts Atossa Therapeutics Price Target to $4 From $7, Maintains Buy Rating	22-02-02	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.57 USD

Average target price

4.667 USD

Spread / Average Target

+197.24%

High Price Target

6 USD

Spread / Highest target

+282.17%

Low Price Target

4 USD

Spread / Lowest Target

+154.78%